Last reviewed · How we verify
Foster® NEXThaler® 100/6 µg/unit dose
Foster® NEXThaler® 100/6 µg/unit dose is a Inhaled corticosteroid/long-acting beta-2 agonist (ICS/LABA) combination Small molecule drug developed by Chiesi Farmaceutici S.p.A.. It is currently in Phase 3 development for Asthma maintenance therapy, Chronic obstructive pulmonary disease (COPD) maintenance therapy.
Foster NEXThaler combines beclomethasone dipropionate (an inhaled corticosteroid) and formoterol (a long-acting beta-2 agonist) to reduce airway inflammation and improve bronchial smooth muscle relaxation in asthma and COPD.
Foster NEXThaler combines beclomethasone dipropionate (an inhaled corticosteroid) and formoterol (a long-acting beta-2 agonist) to reduce airway inflammation and improve bronchial smooth muscle relaxation in asthma and COPD. Used for Asthma maintenance therapy, Chronic obstructive pulmonary disease (COPD) maintenance therapy.
At a glance
| Generic name | Foster® NEXThaler® 100/6 µg/unit dose |
|---|---|
| Sponsor | Chiesi Farmaceutici S.p.A. |
| Drug class | Inhaled corticosteroid/long-acting beta-2 agonist (ICS/LABA) combination |
| Target | Glucocorticoid receptor (beclomethasone); beta-2 adrenergic receptor (formoterol) |
| Modality | Small molecule |
| Therapeutic area | Respiratory/Pulmonology |
| Phase | Phase 3 |
Mechanism of action
Beclomethasone dipropionate acts as a potent anti-inflammatory agent by binding to glucocorticoid receptors in the airways, suppressing inflammatory cell recruitment and cytokine production. Formoterol is a long-acting beta-2 agonist that stimulates beta-2 adrenergic receptors on bronchial smooth muscle, causing bronchodilation and improved airflow. The combination provides both anti-inflammatory and bronchodilatory effects for sustained symptom control.
Approved indications
- Asthma maintenance therapy
- Chronic obstructive pulmonary disease (COPD) maintenance therapy
Common side effects
- Tremor
- Headache
- Palpitations
- Oral candidiasis
- Nervousness/anxiety
- Muscle cramps
Key clinical trials
- Respiratory and Peripheral Muscle Strength as Predictors of Inhaler Treatment Response in Asthma: A Comparison of DPI and MDI Devices (NA)
- A Study to Evaluate the Onset of Relief From Methacholine-induced Bronchoconstriction With CHF1535 NEXThaler in Asthmatic Patients. (PHASE2)
- A Study in Patients With Asthma (PHASE3)
- Study to Assess the Effect of the NEXThaler® Device (DPI - Dry Powder Inhaler) on the Central and Peripheral Airway Dimensions in Asthmatic Patients (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Foster® NEXThaler® 100/6 µg/unit dose CI brief — competitive landscape report
- Foster® NEXThaler® 100/6 µg/unit dose updates RSS · CI watch RSS
- Chiesi Farmaceutici S.p.A. portfolio CI
Frequently asked questions about Foster® NEXThaler® 100/6 µg/unit dose
What is Foster® NEXThaler® 100/6 µg/unit dose?
How does Foster® NEXThaler® 100/6 µg/unit dose work?
What is Foster® NEXThaler® 100/6 µg/unit dose used for?
Who makes Foster® NEXThaler® 100/6 µg/unit dose?
What drug class is Foster® NEXThaler® 100/6 µg/unit dose in?
What development phase is Foster® NEXThaler® 100/6 µg/unit dose in?
What are the side effects of Foster® NEXThaler® 100/6 µg/unit dose?
What does Foster® NEXThaler® 100/6 µg/unit dose target?
Related
- Drug class: All Inhaled corticosteroid/long-acting beta-2 agonist (ICS/LABA) combination drugs
- Target: All drugs targeting Glucocorticoid receptor (beclomethasone); beta-2 adrenergic receptor (formoterol)
- Manufacturer: Chiesi Farmaceutici S.p.A. — full pipeline
- Therapeutic area: All drugs in Respiratory/Pulmonology
- Indication: Drugs for Asthma maintenance therapy
- Indication: Drugs for Chronic obstructive pulmonary disease (COPD) maintenance therapy
- Compare: Foster® NEXThaler® 100/6 µg/unit dose vs similar drugs
- Pricing: Foster® NEXThaler® 100/6 µg/unit dose cost, discount & access